Santrell Hart Moreland
Optometrist · Ellenwood, GANPI 1376613968
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.9%), travel and lodging and entertainment — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Alcon at 26.7% of the total. Among optometrist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $53.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- Coopervision Inc.$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Sun Pharmaceutical Industries Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$971
- Oyster Point Pharma, Inc.$707
- plus $3K from 15 others
What the payments were for
- Travel & lodging$6,25443%
- Food & beverage$8,26357%
- Entertainment$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 60 | $3,874 |
| Coopervision Inc. | 14 | $2,632 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 33 | $2,002 |
| Sun Pharmaceutical Industries Inc. | 50 | $1,650 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $971 |
| Oyster Point Pharma, Inc. | 23 | $707 |
| Bausch & Lomb Americas Inc. | 21 | $593 |
| Harrow Eye, LLC | 13 | $404 |
| Glaukos Corporation | 3 | $281 |
| Novartis | 14 | $276 |
| Dompe US, Inc. | 4 | $262 |
| AbbVie(2 entities) | 8 | $242 |
| Johnson & Johnson Vision Care, Inc. | 3 | $163 |
| Kala Pharmaceuticals, Inc. | 6 | $125 |
| Sight Sciences, Inc. | 1 | $121 |
| Tarsus Pharmaceuticals, Inc. | 3 | $77 |
| Aerie Pharmaceuticals, Inc. | 2 | $39 |
| Thea Pharma Inc. | 1 | $35 |
| Optos, Inc. | 2 | $33 |
| Quidel Corporation | 1 | $30 |
| LKC Technologies, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MyDay Contact Lens$2,147
- BIOTRUE$1,116
- ULTRA$1,116
- DAILIES$1,033
- TearScience Lipiflow System$710
- TearScience Lipiview System$710
- TearScience Lipiscan System$710
- AIR OPTIX$606
- CEQUA$570
- EYSUVIS$248
- TYRVAYA$243
- TOTAL30$126
- DAILIES TOTAL1$126
- Precision 1$126
- TRYPTYR$123
- VUITY$122
- OMNI(R) SURGICAL SYSTEM (US)$121
- KXL System$119
- Photrexa$119
- VEVYE$115
How this compares
$14,535 in reported general payments places this provider in the 95th percentile of 1,285 optometrist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 64 | $26,995 |
| RestasisCyclosporine | 13 | $20,546 |
| TyrvayaVarenicline Tartrate | 23 | $20,472 |
| CequaCyclosporine | 22 | $19,264 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $17,159 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $8,705 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $6,188 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $4,059 |
| Latanoprost | 111 | $2,588 |
| Brimonidine Tartrate | 36 | $2,121 |
| Timolol Maleate | 16 | $554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $242 | $29,25142 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $593 | $26,99564 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $707 | $20,47223 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,650 | $19,26422 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $39 | $17,15924 claims |
| AlconSimbrinza | $3,874 | $4,05919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,285 optometrist providers in Georgia.
Other optometrist in Ellenwood
- Joshua JohnstonAtlanta$993K
- John WomackCanton$931K
- Naheed AhmadRoswell$296K
- Scott MoscowRoswell$278K
- Stephen SummerowPerry$222K
- Janelle DavisonSmyrna$199K
- Keyle BrownDawsonville$182K
- Nacondus GambleFort Stewart$175K
- Amber ZaunbrecherAtlanta$99K
- Jeffrey CofieWarner Robins$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.